A33 CLINICAL STUDIES IN OBSTRUCTIVE LUNG DISEASE: Treatment Of Acute Exacerbations In COPD: An Exploratory Phase Ii Study Of Single And Repeated Doses Of Acumapimod (bct197), An Oral P38 Inhibitor

Mitogen-activated protein kinase (MAPK) p38, a key regulator in the inflammation pathway, is activated in the lungs of patients with COPD. Conclusions: Short-term treatment with the p38 inhibitor acumapimod showed clinically relevant improvement of 152mL increase in FEV 1 versus placebo in AECOPD at...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of respiratory and critical care medicine Vol. 195
Main Authors Strambu, I, Parkin, J M, Magnusson, B, MacKinnon, A
Format Journal Article
LanguageEnglish
Published New York American Thoracic Society 01.01.2017
Subjects
Biomedical research
Chronic obstructive pulmonary disease
Health risk assessment
Kinases
Patients
Trends
Online AccessGet full text

Cover

More Information
Summary:Mitogen-activated protein kinase (MAPK) p38, a key regulator in the inflammation pathway, is activated in the lungs of patients with COPD. Conclusions: Short-term treatment with the p38 inhibitor acumapimod showed clinically relevant improvement of 152mL increase in FEV 1 versus placebo in AECOPD at Day 8, with dose-dependent trends in biochemical markers of inflammation, patient-reported outcomes and hospital stay.
ISSN:1073-449X
1535-4970